S47 Hypertonic saline inhaled therapy – results of drug reaction assessments. (15th November 2017)

• Record Type: Journal Article
• Authors: Rinaldi, G; Housley, G; Shah, A; Dennis, B; Loebinger, M
• Is Part Of: Thorax. Volume 72(2017)Supplement 3
• Page Start: A31
• Page End: A31
• Publication Date: 2017-11-15
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2017-210983.53
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction: Hypertonic saline (HTS) is commonly nebulised used to aid airway clearance in patients with chronic suppurative lung disease. In view of the risk of bronchoconstriction, prior to starting HTS, patients undergo a drug reaction assessment (DRA), as suggested by guidelines. 1 Patients that experience a>15% reduction in FEV1 post inhalation, +/-lack of tolerability, are deemed to have failed the DRA and would not usually be prescribed it for continued usage. We aimed to identify patient characteristics predicting a successful DRA and the likelihood of continuing HTS at 1 year post DRA. Methods: A retrospective analysis of all HTS DRAs between April 2011 and March 2016 at the Royal Brompton Hospital was undertaken. Spirometry, age, gender and underlying disease were recorded and the variables associated with DRA success and continued use at 1 year were assessed with logistic regression. Results: 523 patients underwent an HTS DRA with overall 89.5% passing the test. There were 504 tests with 7% HTS (90.2% passed) and 18 tests with 3.5% HTS (73.7% passed). A higher FEV1% Predicted Pre-Trial (PPT) was significantly associated with passing the DRA with an Odds Ratio (OR) of 0.97 (95%CI: 0.95–0.98, p-value<0.001); patients with an FEV% PPT >61% had a 0.05% chance of failing the DRA. Patients diagnosed with ABPA or COPD were significantly more likely to fail the DRA for HTS with ORs of 3.07 (95%CI:1.15–8.1, p-value=0.025) and 3.38 (95%CI:1.06–10.76, p-value-0.039), respectively. Amongst the 468 patients who passed the DRA, those with a higher FEV1% PPT were also more likely to remain on the HTS after 12 months, whilst, non-CF Bronchiectasis (OR: 0.44, p-value=0.020) and patients with "Other" lung diseases, including carcinoma and sarcoidosis, (OR:0.33, p-value=0.008) patients were significantly less likely to remain on it. Conclusions: The vast majority of patients passed the HTS DRA test and the failure rate in those with FEV1 PPT >61% was extremely low. We propose that clinical phenotypes could be used to risk assess patients who need HTS DRA tests before starting HTS. Reference: Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(1):i1–58. doi:10.1136/thx.2010.136119